Johnson And Johnson's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Johnson And Johnson (JNJ) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Johnson And Johnson vs Its Competitors
- TTM: Trailing 12-month revenue of 97,929M vs 1,320,810M combined for tracked competitors (6.9% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+3.4% annualized vs trailing 12 months), vs accelerating (+3.2%) for its tracked peer group.
- Growth: Johnson And Johnson generated 6.6% revenue growth year over year in Q2 2026, vs 8.8% for its tracked competitors combined.
- Profitability: Its 21.9% net margin compares with 5.7% for the peer group.
- Scale: Johnson And Johnson ranks #2 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 12.1% of industry market cap.
- Peer revenue share: Johnson And Johnson accounted for 6.9% of combined revenue among its tracked peer group, down from 7.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.70M compares with $0.87M for the peer group (0.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
JNJ Sales vs. its Competitors, Q2 2026
Johnson And Johnson reported revenue growth of 6.60 % year on year in Q2 2026, below its competitors' combined revenue growth of 8.78 %.
With a net margin of 21.86 %, Johnson And Johnson achieved higher profitability than its competitors (5.68 %).
Johnson And Johnson generated 6.91 % of the combined sales of its peer group, down from 7.04 % a year earlier.
Johnson And Johnson vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Johnson And Johnson and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Johnson and Johnson | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (63) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Johnson And Johnson's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 6.6% for Johnson And Johnson. Johnson And Johnson's share of combined industry revenue moved from 3.31% to 3.29%, a loss of 0.02 percentage points.
Johnson And Johnson's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Johnson and Johnson | Yes | Yes | Yes | No |
| Competitors combined (219) | ||||
| High-Confidence Competitors (87) | ||||
| Similar-Size Competitors (6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
JNJ Stock Performance relative to its Competitors
JNJ Stock Performance relative to High-Confidence Competitors
JNJ Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Moderna Inc | 282.9% | Outperformed |
| 3 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 4 | Horizon Kinetics Holding Corporation | 282.9% | Outperformed |
| 5 | Dupont De Nemours Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Johnson And Johnson's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Johnson And Johnson's Comment on Competition and Industry Peers
Publicly Traded Peers of Johnson and Johnson
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Johnson and Johnson | 663,585.20 | 97,929.00 |
| Eli Lilly And Company | 1,058,837.89 | 79,665.80 |
| Beone Medicines Ltd | 552,467.82 | 6,128.24 |
| Abbvie Inc | 471,581.88 | 64,386.00 |
| Merck and Co Inc | 367,264.30 | 66,569.00 |
| Procter and Gamble Co | 361,061.51 | 87,032.00 |
| SUBTOTAL | 7,192,054.22 | 1,794,587.59 |
Sign in to see all competitors of Johnson and Johnson.
Sources: Johnson and Johnson's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Johnson and Johnson versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Johnson And Johnson's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Angiodynamics Inc | Named by the company | 85% |
| Intuitive Surgical Inc | Named by the company | 85% |
| Co diagnostics Inc | Named by the company | 85% |
| Encision Inc | Named by the company | 85% |
| United Health Products Inc | Named by the company | 85% |
| Akero Therapeutics Inc | Named by the company | 85% |
| Pulse Biosciences Inc | Named by the company | 85% |
| Glucotrack Inc | Named by the company | 85% |
| Alphatec Holdings Inc | Named by the company | 85% |
| Spyglass Pharma Inc | Named by the company | 85% |
| The Honest Company Inc | Named by the company | 85% |
| Invo Fertility Inc | Named by the company | 85% |
| Bicara Therapeutics Inc | Named by the company | 85% |
| Starco Brands Inc | Named by the company | 85% |
| Medinotec Inc | Named by the company | 85% |
| Candel Therapeutics Inc | Named by the company | 85% |
| Spyre Therapeutics Inc | Named by the company | 85% |
| Morphic Holding inc | Named by the company | 85% |
| The Cooper Companies Inc | Named by the company | 85% |
| Voyager Therapeutics Inc | Named by the company | 85% |
| Ngm Biopharmaceuticals Inc | Named by the company | 85% |
| Enovis Corp | Named by the company | 85% |
| Addex Therapeutics Ltd | Named by the company | 85% |
| Prestige Consumer Healthcare Inc | Named by the company | 85% |
| Fusion Pharmaceuticals Inc | Named by the company | 85% |
| Alpha Pro Tech Ltd | Named by the company | 85% |
| Reshape Lifesciences Inc | Named by the company | 85% |
| Gridai Technologies Corp | Named by the company | 85% |
| Ss Innovations International Inc | Named by the company | 85% |
| Surrozen Inc | Named by the company | 85% |
| INVO | Named by the company | 85% |
| Lineage Cell Therapeutics Inc | Named by the company | 85% |
| Bioventus Inc | Named by the company | 85% |
| Shattuck Labs Inc | Named by the company | 85% |
| Mangoceuticals Inc | Named by the company | 85% |
| Compass Therapeutics Inc | Named by the company | 85% |
| Vincerx Pharma Inc | Named by the company | 85% |
| NAYA | Named by the company | 85% |
| Bright Minds Biosciences Inc | Named by the company | 85% |
| Abivax Sa | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Johnson And Johnson's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Johnson And Johnson's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Johnson and Johnson | Oncology 29.26 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Procter and Gamble Co | Fabric & Home Care 34.83 % |
| Thermo Fisher Scientific Inc | Clinical Research 19.98 % |
| Amgen Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Johnson and Johnson.
Johnson And Johnson's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Johnson and Johnson | 663,585 | 695,518 | 149,411 |
| Eli Lilly And Company | 1,058,838 | 1,593,316 | 534,224 |
| Beone Medicines Ltd | 552,468 | 510,686 | 54,642 |
| Abbvie Inc | 471,582 | 1,129,579 | 110,807 |
| Merck and Co Inc | 367,264 | 887,587 | 42,267 |
| Procter and Gamble Co | 361,062 | 836,846 | 155,231 |
| PEERS TOTAL | 6,528,469 | 874,845 | 88,140 |
Sign in to see all peers for Johnson and Johnson.
Johnson And Johnson's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 57.42 % |
| Eli Lilly And Company | United States 61.21 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Procter and Gamble Co | Non-US 52.05 % |
| Thermo Fisher Scientific Inc | North America 51.27 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Johnson and Johnson.
Johnson And Johnson's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Johnson And Johnson's industry classification, broader than the peer set above. Market cap in millions of $.Johnson And Johnson ranks #2 of 498 companies by market capitalization in its industry, holding 12.13 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Johnson And Johnson's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Johnson And Johnson's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 66.38 % |
| 2 | Johnson and Johnson | 664,610 | 53.25 % |
| 3 | Beone Medicines Ltd | 545,679 | 10.28 % |
| 4 | Abbvie Inc | 1,234 | 12.3% |
| 5 | Merck and Co Inc | 1,234 | 12.3% |
| 6 | Novartis Ag | 1,234 | 12.3% |
| 7 | Abbott Laboratories | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Johnson And Johnson's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Johnson And Johnson's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 67.91 % | 64.89 % (avg) | +3.0 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | 36.20 % | -7.21 % (avg) | +43.4 pp |
| Capital Intensity (Capex / Revenue) | 5.48 % | 4.92 % (avg) | +0.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Johnson And Johnson's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 27.0x | 25.1x | +1.9x |
| EV / EBITDA | 16.9x | 17.3x | -0.4x |
| P/B | 7.0x | 4.5x | +2.5x |
| Return on Equity | 25.74 % | industry aggregate | 8.49 % |
| Return on Invested Capital | - | -2.95 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Johnson And Johnson's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 6.71 % | 0.59 % | 0.64 % | 13.55 % | 1.25 % | -2.02 % | -4.52 % | 6.05 % |
| Operating Margin | 24.27 % | 24.15 % | 23.60 % | 24.95 % | 40.01 % | 22.80 % | 23.42 % | 26.85 % |
| Return on Invested Capital | 10.45 % | 10.94 % | 10.12 % | 11.12 % | 17.95 % | 10.40 % | 10.42 % | 10.61 % |
| P/E | 24.3x | 25.1x | 27.7x | 21.3x | 25.9x | 11.3x | 26.8x | 17.9x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Johnson And Johnson's BCG Growth-Share Matrix
Relative market share (vs Johnson And Johnson's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Johnson And Johnson falls in the Dog quadrant: relative market share of 0.63x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Johnson And Johnson's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 5.48 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Johnson And Johnson's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Johnson And Johnson's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Johnson And Johnson's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Johnson And Johnson falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Johnson And Johnson's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 8.5 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+3.4% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
No rule matched.
Opportunities
- A meaningful share of tracked competitors (32.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Johnson And Johnson's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Procter and Gamble Co | 0.25 | 0.71 | 0.71 |
Sign in to see all peers for Johnson and Johnson.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Johnson And Johnson's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Procter and Gamble Co | Q2 2026 | +1.5 % | -15.0 % |
| PEERS TOTAL | +5.3 % | +3.6 % |
Sign in to see all peers for Johnson and Johnson.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Johnson And Johnson's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Procter and Gamble Co | Q2 2026 | +2.7 % | +2.7 % |
Sign in to see all peers for Johnson and Johnson.
Johnson And Johnson's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Procter and Gamble Co | 12.72% | 17.81% | 30.05% |
Sign in to see all peers for Johnson and Johnson.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Johnson And Johnson's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Johnson and Johnson | 31.48 | 6.78 |
| Eli Lilly And Company | 39.77 | 13.29 |
| Beone Medicines Ltd | 834.09 | 90.15 |
| Abbvie Inc | 75.22 | 7.32 |
| Merck and Co Inc | 119.91 | 5.52 |
| Procter and Gamble Co | 22.62 | 4.15 |
| PEERS AVERAGE | 37.46 | 4.01 |
Sign in to see all peers for Johnson and Johnson.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.